Diagnostics Company SIRS-Lab Insolvent

The German biotechnology company SIRS-Lab has requested the opening of insolvency proceedings. The company, founded ten years ago, develops molecular diagnostic technologies for lifethreatening infections such as sepsis which claims 250.000 victims per year in the USA alone. SIRS-Lab has developed a new diagnostic system which detects pathogens in a fast and reliable way and therefore allows an efficient therapy. The testingsystem is close to market introduction. As provisional insolvency administrator Rolf Rattunde now heads the Jena based company with all 30 employees and is searching for investors.

At the end of December SIRS-Lab requested the opening of insolvency proceedings because the public and private shareholders could not agree upon a further funding. Yesterday the District Court of Gera, Germany, appointed Rolf Rattunde of Leonhardt Rechtsanwalte Erfurt as provisional insolvency administrator.

'SIRS-Lab has developed an innovative diagnostic technology for sepsis, also known as blood poisoning. At the end of last year, a clinical study about the efficiency of the new pathogen test could be finished successfully. In order to bring the test tomarket, further investments are necessary upon which the current shareholders cannot agree.Therefore, we are now searching for investors for this very interesting diagnostics company. The first meetings with management and employees made me very confident to proceed with operations. The salaries of the 30 SIRS-Lab employees are currently secured through the publicly funded insolvency compensation payment,' comments Prof. Rolf Rattunde from Leonhardt Rechtsanwalte Erfurt.

In addition to novel testing systems for the early detection of life-threatening infections, SIRS-Lab develops and commercializes technologies to improve the performance of molecular tests for many applications. That includes a patented technology to raise the sensitivity of pathogen assays which are used in bloodstream infections.